Pricing the Cycle

Figures converted from Indonesian rupiah at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Pricing the Cycle

At $0.169 CPIN trades at 8.9x record FY2025 EPS but about 14x its own ten-year-average EPS, and the record it is measured against was made entirely downstream — broiler result rose 64.9% to $201m while feed slipped to $230m — so the low multiple is a peak, downstream-driven denominator rather than a discount to normalized value. At the 15 July 2026 price the stock is also 7.5x the last twelve months — cheap for the market leader on the surface. On the mid-cycle profit power the last decade delivered, the same price is roughly 11–14x; the ~33% de-rating has moved the stock from pricing the peak toward pricing something nearer the average, neither the bargain the headline implies nor obviously expensive.

The denominator choice is the whole valuation. At a 12–13x market multiple, mid-cycle EPS in the $0.013–0.017 band the last decade delivered implies a price of roughly $0.15–0.20, while the record $0.021 EPS at the same multiple implies $0.23+; at $0.169 the stock already sits inside that mid-cycle range, not beneath it. The strongest fact the other way is that the base may still be rising: Q1 2026 net profit of $155m ran about 67% above Q1 2025's $92m, so the trailing denominator is climbing rather than topping.

Sources: share price and market data as of 16 July 2026; FY2025 net profit $339m and EPS $0.021 [1]; dividend per share [2].

The company reported a record FY2025 net profit of $339m, or $0.021 per share, on 16,398,000,000 shares [3] [4]. The valuation depends on which earnings number a buyer capitalises — and this business has swung from $0.009 per share in the FY2023 trough to $0.021 in FY2025 [5], a 2.4x range across three years.

What the multiple is capitalising

The chart below sets the last ten years of earnings per share against the two averages that bracket a reasonable mid-cycle: the six-year post-restatement mean ($0.015) and the ten-year mean ($0.014). FY2025's $0.021 sits about 55% above that mid-cycle band; the FY2023 trough sat about 37% below it.

Source: earnings per share FY2016–FY2025, derived from reported net profit attributable to owners and a constant 16,398,000,000 shares; FY2023–FY2025 figures per the Summary of Financial Highlights [6].

Constant shares across the decade make the EPS series a clean read on earning power — no dilution or buybacks distort it [7]. The pattern is the cycle the earlier chapters traced: a downstream-driven peak in FY2018 and FY2025, a trough in FY2023, and a feed-anchored floor that has never produced a loss year. What it is not is a smooth compounding line a single-multiple valuation would suit.

The multiple and the denominator

Applying the $0.169 price to each plausible earnings base shows how wide the answer runs. On the record and trailing figures the stock looks visibly cheap; on any mid-cycle measure it is a full-to-fair multiple for a cyclical.

Sources: EPS bases derived from reported financials FY2016–FY2025 [8]; trailing and forward figures per market data and consensus estimates as of 16 July 2026.

The trailing multiple is the most misleading of the set. It reads 7.5x because the twelve months to Q1 2026 captured a further profit surge — Q1 2026 net profit rose to $155m from $92m a year earlier on higher chicken prices and volume. That is the top of the spread cycle feeding into the denominator, not a durable run-rate. The honest anchors are the mid-cycle rows: on the profit power the business has averaged since the FY2020 revenue restatement, $0.169 is about 11–14 times earnings.

Book value and returns give the same reading

A second lens removes the earnings-cyclicality problem by valuing the equity against its own book. CPIN carried $2.05bn of equity at year-end FY2025 — about $0.125 per share — so $0.169 is roughly 1.5 times book [9]. Against a FY2025 return on equity of 16.5%, 1.5x book implies a through-price earnings yield near 11% — the same order as the mid-cycle P/E, and consistent rather than contradictory.

Source: shareholders' equity and return on equity, FY2023–FY2025 Summary of Financial Highlights [10].

The balance sheet also removes the leverage question a cyclical usually carries. CPIN sits on roughly $98m of net cash, so enterprise value (about $2.67bn) is slightly below the equity market cap and an EV/EBITDA calculation would land close to the P/E reading rather than inflating it. There is no debt drag on the multiple — a point that matters more in a downturn, where a leveraged peer's equity multiple stretches as profit falls.

The income lens is softer than the headline. The FY2025 dividend of $0.011 per share, approved at the May 2026 AGM, is a 5.9% yield at $0.169 [11]. But the payout tracks cash, not a progressive commitment — it was $0.007 the year before (a 3.5% yield) and zero for FY2022 — so the yield is a by-product of a good year, not a floor to underwrite.

The de-rating in peer context

The clearest evidence that the market is repricing the cycle rather than the company is the divergence inside the sector. Over the twelve months to mid-July 2026 CPIN's market capitalisation fell about 34% (from roughly $4.20bn to $2.79bn) while Japfa Comfeed's rose about 41% (from $0.92bn to $1.30bn). The market narrowed CPIN's premium over its nearest integrated rival even as CPIN out-earned it — a rotation toward the cheaper, more downstream-levered name as the spread recovery matured, not a verdict on relative quality.

Source: market data, twelve-month change to 16 July 2026 (third-party market aggregators).

Two arm's-length marks sit well above spot. Sell-side consensus (11 analysts, a Buy skew) carries a mean 12-month target near $0.275, about 63% above $0.169; a published discounted-cash-flow estimate puts intrinsic value around $0.283, about 68% above. Both implicitly capitalise an earnings base nearer the record than the trough. The disagreement is about the denominator: the Street values CPIN on sustained high-single-digit profit growth, while the share price has drifted toward a mid-cycle number.

What the price implies, and what would decide it

Reduced to arithmetic: at $0.169 the market pays about 8.9x the record year and about 13x the ten-year average. Which of those is the right anchor is the same question the downstream and moat chapters left open — where the government-managed broiler spread settles once FY2026 normalises. If mid-cycle earning power holds near the $0.013–0.017 band the last decade delivered, the stock is fairly-to-fully valued around 11–14x and the ~33% de-rating was largely rational repricing of a peak. If the structural margin premium the leader has shown over peers (Competitive Moat) — an 8% net margin against Malindo's 3%, never a loss year — lifts the through-cycle average above history, then capitalising even $0.018 of normalised EPS at a market multiple leaves clear upside, which is where consensus and the DCF sit.

The strongest fact against reading today's price as cheap: the mid-cycle multiple is not low. A cyclical whose swing factor is set by government supply policy, trading at 13x its own ten-year average earnings with a variable dividend, is priced for the recovery to hold, not for distress. The strongest fact for the bull is quality-adjusted — this is the net-cash market leader earning a 16.5% ROE, and the cash-conversion work (Cash Conversion) confirmed the earnings are real money, not accrual.

The checkable items that resolve it are narrow and near. Reported broiler average selling prices and DOC placement volumes through 2026 are the direct read on whether the spread is normalising or oversupplying; the FY2026 result lands against the consensus $0.021 EPS on 31 July 2026; and the payout on FY2025-basis cash flags management's own read of durable earning power. Each is a line in the next filing, not a matter of opinion.